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Streptococcus pneumoniae isolates (N = 31,001) were
collected from patients with community-acquired respirato-
ry tract infections during the PROTEKT US surveillance
study (2000–2003). While the macrolide (erythromycin)
resistance rate remained stable at ≈29%, the prevalence of
resistant isolates containing both erm(B) and mef(A)
increased from 9.7% in year 1 to 16.4% in year 3, with sub-
stantial regional variability. Almost all (99.2%) dual
erm(B)+mef(A) macrolide-resistant isolates exhibited mul-
tidrug resistance, whereas 98.6% and 99.0% were lev-
ofloxacin- and telithromycin-susceptible, respectively.
These strains were most commonly isolated from the ear or
middle-ear fluid of children. Of 152 representative
erm(B)+mef(A) isolates, >90% were clonally related to the
multidrug-resistant international Taiwan19F-14 clonal com-
plex 271 (CC271). Of 366 erm(B)+mef(A) isolates from the
PROTEKT global study (1999–2003), 83.3% were CC271,
with the highest prevalence seen in South Africa, South
Korea, and the United States. This study confirms the
increasing global emergence and rapidly increasing US
prevalence of this multidrug-resistant pneumococcal clone.
S
treptococcus pneumoniae is a key pathogen implicated
in community-acquired respiratory tract infections,
including acute otitis media (1), community-acquired
pneumonia (2), acute exacerbations of chronic bronchitis
(3), and acute bacterial sinusitis (4). During the last
decade, the clinical management of respiratory infections
has become increasingly complicated by the emergence
and spread of resistance in S. pneumoniae to commonly
used antibacterial drugs, particularly β-lactams and
macrolides, both in the United States (5–10) and world-
wide (11–13). PROTEKT (Prospective Resistant
Organism Tracking and Epidemiology for the Ketolide
Telithromycin) is an international, longitudinal surveil-
lance study initiated in 1999 to evaluate the activity of
telithromycin, a new ketolide antibacterial drug, against S.
pneumoniae and other common respiratory pathogens and
to compare its activity with other antibacterial drugs (13).
In addition, the integration of genotypic testing into PRO-
TEKT has helped elucidate the international molecular
epidemiology of resistant strains (14,15).
PROTEKT US is a sister program to the PROTEKT
global study that was initiated in 2000, specifically to
monitor antibacterial resistance in the United States. Data
from PROTEKT US showed an overall pneumococcal
macrolide (erythromycin) resistance rate of 31.0% in 2000
and 2001 (9). Macrolide resistance in S. pneumoniae is
mediated by 2 major mechanisms: methylation of riboso-
mal macrolide target sites, encoded by the erm(B) gene,
and drug efflux, encoded by mef(A) (14–17). While
erm(B) is the dominant genotype across much of the
world,  mef(A)-mediated mechanisms of resistance pre-
dominate in the United States (14). Recently, PROTEKT
and other studies have identified S. pneumoniae isolates
with both erm(B) and mef(A) genes in the United States,
Canada, South Korea, China, South Africa, Japan, Mexico,
and Hungary (14,15,18–22). The initial confirmation of
isolates with both erm(B) and mef(A) was first described in
the South African study (19). These dual erm(B)+mef(A)
isolates belong predominantly to 1 major clonal complex
(15) and show high rates of resistance to multiple classes
of antibacterial drugs; consequently, their potential spread
is of serious concern.
We report the prevalence of the multidrug-resistant
erm(B)+mef(A) clonal complex in the United States. In
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Methods
For the PROTEKT US study, isolates of S. pneumoniae
were collected from across the United States from 2000 to
2003. The numbers of collection centers that provided
samples were 207 in year 1 (2000–2001), 241 in year 2
(2001–2002), and 247 in year 3 (2002–2003).
Pathogenic respiratory tract isolates of S. pneumoniae
were collected from adult and pediatric outpatients with
community-acquired respiratory tract infections (acute oti-
tis media, pneumonia, acute exacerbations of chronic
bronchitis, acute exacerbations of chronic obstructive pul-
monary disease, and sinusitis). Also included were isolates
cultured from material collected from hospitalized patients
within 48 hours of admission. The following sources were
considered acceptable: cultures from blood, sputum, bron-
choalveolar lavage, middle-ear fluid (collected by tympa-
nocentesis), nasopharyngeal swab or aspirate, and sinus
aspirate. Patients with nosocomial respiratory tract infec-
tions and those with cystic fibrosis were excluded.
Duplicate strains, or strains originating from existing col-
lections, were also not included in the study. Demographic
data collected included the age and sex of the patient,
infection, culture source, inpatient versus outpatient status,
specimen accession number, and date of sample collection.
Details of the methods for isolate storage, transportation,
and identification have been reported previously (23).
MICs were determined at a central laboratory (CMI,
Portland, OR, USA) by using the Clinical and Laboratory
Standards Institute (CLSI) broth microdilution method
(24). The following antibacterial agents were tested:
amoxicillin-clavulanate (amoxicillin alone was not tested;
however, susceptibility can be extrapolated from the
amoxicillin-clavulanate results), azithromycin, cefurox-
ime, clarithromycin, clindamycin, co-trimoxazole, eryth-
romycin, levofloxacin, linezolid, penicillin, telithromycin,
and tetracycline. In all cases, CLSI MIC interpretive crite-
ria were used to define susceptibility and resistance (25).
Susceptibility to telithromycin was determined by using
the CLSI breakpoints (25): susceptible <1 µg/mL; interme-
diate 2 µg/mL; resistant >4 µg/mL.
All erythromycin-resistant (MIC >1 µg/mL) pneumo-
coccal isolates collected from PROTEKT US years 1–3
were analyzed for the presence of erm(B), erm(A) subclass
erm(TR), and mef(A) macrolide resistance genes. Isolates
in year 1 were analyzed by multiplex rapid-cycle poly-
merase chain reaction (PCR) with microwell-format probe
hybridization, as described previously (26). In years 2 and
3, isolates were analyzed by using a multiplex TaqMan
(Applied Biosystems, Foster City, CA, USA) PCR assay
that was validated against the previous PCR method (27).
A proportion of dual erm(B)+mef(A) macrolide-resist-
ant isolates underwent serotyping and multilocus sequence
type (MLST) determination at G.R. Micro Ltd (London,
UK). Isolates were serotyped by using antisera from the
Statens Serum Institute (SSI, Copenhagen, Denmark).
MLST was determined as described previously (15). 
Serotyping and MLSTdetermination were also conduct-
ed on 366/378 dual erm(B)+mef(A) macrolide-resistant S.
pneumoniae isolates, respectively, collected from the glob-
al PROTEKT study (1999–2003). Sequence type (ST) and
alleles were analyzed by UPGMA (unweighted pair group
method with arithmetic mean) and BURST (based upon
related STs) analysis by using the START program (version
1.0.5 [28]) to assign lineage and clonal complexes.
Results
Macrolide Resistance Mechanisms 
From 2000 to 2003, a total of 31,001 S. pneumoniae iso-
lates were collected as part of the PROTEKT US study:
10,103 in year 1, 10,012 in year 2, and 10,886 in year 3.
The proportion of S. pneumoniae isolates resistant to eryth-
romycin was similar across years 1, 2, and 3 of the PRO-
TEKT US study (29.4% overall). The prevalence of mef(A)
in macrolide-resistant isolates decreased from 68.8% in
year 1 to 67.3% in year 2 and to 63.9% in year 3, while the
prevalence of erm(B) alone appeared stable (16.9% in year
1, 16.5% in year 2, 16.5% in year 3). By contrast, an
increase was seen in the prevalence of macrolide-resistant
strains carrying both erm(B) and mef(A) genes; by year 3,
16.4% of isolates were of this genotype (Table 1). When
considered as a proportion of all S. pneumoniae isolates
collected in year 3, a total of 520 (4.8%) of 10,886 were
positive for both erm(B) and mef(A). 
Geographic differences were observed in the preva-
lence of erm(B)+mef(A)–encoded resistance across the
United States, from 10.3% in the Southeast to 23.9% in the
North-Central region (year 3). The prevalence of this
genotype increased in all regions between years 1 and 3
(Table 1).
The largest increases in erm(B)+mef(A)-encoded resist-
ance during the 3-year study period occurred in isolates
collected from pediatric patients (Table 2). By year 3, iso-
lates exhibiting this genotype made up 254 (22.7%) of
1,119 isolates obtained from pediatric patients (<14 years
of age) compared with 98 (12.3%) of 794 isolates collect-
ed from patients >64 years of age. Patients in the 0- to 2-
year age group had the highest prevalence (23.9%) of dual
erm(B)+mef(A) resistance (Table 2). 
RESEARCH
852 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 6, June 2005Across the 3-year study period, the dual erm(B)+
mef(A) genotype was found most frequently in isolates
collected from the ear or middle-ear fluid (Table 3). In year
3, the prevalence of this form of macrolide resistance was
>30% in isolates collected from either of these sources. By
contrast, isolates cultured from blood samples had the low-
est proportion of dual erm(B)+mef(A)-encoded resistance
(92 [4.6%] of 2,014 isolates in the 3 years). 
Antimicrobial Resistance in 
Dual erm(B)+mef(A) Isolates 
In addition to exhibiting almost universal resistance to
the macrolides tested (azithromycin, clarithromycin, eryth-
romycin), isolates carrying both erm(B) and mef(A) were
highly resistant (>90%) to penicillin, cefuroxime, tetracy-
cline, and co-trimoxazole (Table 4). Resistance to amoxi-
cillin-clavulanate (and hence amoxicillin) was also
common in these isolates (Table 4), and the longitudinal
data showed that the rate of resistance to this antibacterial
drug increased from 29.9% to 43.9% from year 1 to year 3.
Almost all (1,150 [99.2%] of 1,159) of the erm(B)+mef(A)
isolates were multidrug-resistant (i.e., resistant to >2 class-
es of antibacterial drugs).
A total of 16 (1.4%) of the 1,159 dual erm(B)+mef(A)
isolates collected were resistant to levofloxacin; MIC val-
ues for these were as follows: 8 µg/mL (2 isolates), 16
µg/mL (9 isolates), 32 µg/mL (4 isolates), and 128 µg/mL
(1 isolate). One dual erm(B)+mef(A) isolate (<0.1% of the
total) was resistant to telithromycin (MIC 4 µg/mL).
Molecular Epidemiology
The results of MLST determination on 518 S. pneumo-
niae isolates (366 from PROTEKT global [including 35
from the United States] and 152 from PROTEKT US) with
dual  erm(B)+mef(A)–encoded resistance showed 82 ST
variants (Figure). Of these, 21 were in the MLST database,
and 61 were submitted to the database and assigned a new
ST (STs 1407–1467). All of the unique STs were serotyped
and, together with the 20 S. pneumoniae clones listed by
the Pneumococcal Molecular Epidemiology Network (29),
were analyzed for clonal relatedness by using UPGMAand
BURST (Figure). Both the serotype distribution and range
of MLSTs in these isolates were limited (Table 5), with 3
clonal complexes predominating. A phylogenetic analysis
of these variations showed that 45 of the 82 STs were
closely related, either serotype 19F or 19A (Table 5).
These strains were of ancestral ST 271 and hence were
designated clonal complex (CC) 271, which is equivalent
to CC I (15) and CC 236 (22). Overall, 305 (83.3%) of 366
global isolates had MLST profiles consistent with this
clone (Table 6).
Of the 35 isolates collected in the United States from
the PROTEKT global study, all exhibited MLST profiles
and serotypes characteristic of CC 271 (Table 6).
Moreover, analysis of a geographically and chronological-
ly varied sample of 152 S. pneumoniae isolates with dual
erm(B)+mef(A)–encoded resistance collected from the
PROTEKT US study suggested that >90% of dual-resist-
ant isolates in the United States belong to CC 271.
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Pneumococcal macrolide resistance in the United States
is predominantly mediated by the mef(A) gene, which
encodes for lower-level, efflux-mediated resistance (14).
However, the latest surveillance data from PROTEKT US
presented in this article show that the prevalence of this
form of resistance is decreasing. This trend coincides with
the emergence of multidrug-resistant clones of S. pneumo-
niae that express both erm(B) and mef(A). These strains
increased in prevalence from 9.7% of macrolide-resistant
isolates in 2000–2001 to 16.4% in 2002–2003. Moreover,
geographic data indicate that dual erm(B)+mef(A) isolates
are currently even more prevalent in some regions of the
United States (accounting for >20% of macrolide-resistant
strains). By 2002–2003, S. pneumoniae strains with this
dual mechanism of resistance made up almost 5% of all
isolates collected.
The major clinical implication of the present report is the
increased potential for treatment failure with most antibac-
terial drugs currently recommended to empirically treat
community-acquired respiratory tract infections (30,31).
Ear isolates are more prone to represent treatment failure,
and blood isolates represent primary infection; thus, the dra-
matic increase in CC 271 in ear isolates compared to blood
isolates (Table 2) is noteworthy. Almost all dual
erm(B)+mef(A) isolates were highly resistant to multiple
antibacterial drugs, including penicillin, macrolides, tetra-
cycline, and co-trimoxazole. This high-level macrolide
resistance is presumably mediated by the erm(B) gene.
Furthermore, resistance to amoxicillin-clavulanate (and
hence amoxicillin) increased in these isolates from 29.9% to
43.9% during the 3-year surveillance period, which raises
concerns about the potential selection of resistant isolates
through widespread use of this agent for community-
acquired infections, particularly acute otitis media. 
The prevalence of resistance to fluoroquinolones, such
as levofloxacin, was low (1.4% overall) in the dual
erm(B)+mef(A) isolates; however, when present, this
resistance was often high (MIC 8–128 µg/mL).
Telithromycin resistance was rare (<0.1%) in S. pneumoni-
ae isolates with dual erm(B)+mef(A)–encoded macrolide
resistance. 
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clonal groups account for most penicillin-, macrolide-, and
multidrug-resistant  S. pneumoniae in the United States
(18,32). The MLST analysis conducted in the present
study shows that the dual erm(B)+mef(A) macrolide-
resistant S. pneumoniae isolates collected in the United
States from 1999 to 2003 are associated with 3 major glob-
al clones, in addition to a wide variety of other MLST vari-
ations. Most of these isolates belong to 1 major clonal
group; the genotypic profile and serotype distribution of
this predominant group show that it is highly related to an
international erm(B)+mef(A) clonal strain, Taiwan19F-14,
first found in the Far East (22). The designation of clonal
groups is determined by BURST analysis, which assigns
ancestral lineage by the most common ST. For this reason,
the pneumococcal clone designated CC 271 in the present
study was named CC 236 in the study by Ko and Song
(22). To avoid confusion, a common CC nomenclature
(such as the original designation of the clone, CC 1 [15])
may be more useful.
The pneumococcal clone discussed in this paper was
previously identified in the first year (1999–2000) of the
PROTEKT global study (15). The most recent data from
this survey, which covered the period 1999–2003, confirm
that this clone now has a worldwide distribution, with par-
ticularly high incidences in South Africa and South Korea,
as reported in previous studies (15,19,21). Strains carrying
both genes have also been recorded recently in New
Zealand (33), Canada (34), Italy (35), and Scotland (36).
Together with the regional genotyping data, the epidemio-
logic analyses we describe show that this multidrug-resist-
ant CC 271 is now widespread and increasing in
prevalence across the United States.
The widespread emergence of the erm(B)+mef(A)
genotype into varying lineages at the apparent expense of
strains expressing only 1 resistance determinant suggests
that S. pneumoniae carrying this form of resistance has an
evolutionary advantage. Since dual resistant isolates have
drug MICs similar to those observed in strains harboring
erm(B) alone, such an advantage cannot be explained on
the basis of increased macrolide resistance alone. This
clone has previously been shown to contain 2 mobile
genetic elements, Tn1545 and “mega” (15). While the
erm(B) gene is most often present on Tn1545, “mega” is
known to contain the mef(E) variant of mef(A), and this
variant has been shown to be present in CC 271 (15).
Hence, acquisition of 2 mobile genetic elements and asso-
ciated resistance genes is a possible explanation for the
successful emergence of this clone over isolates with only
erm(B) or mef(A); it is not solely the acquisition of the
efflux or methylase gene but the associated resistance
genes on the genetic elements that lead to a multidrug-
resistant clone in which prevalence is driven by greater
environmental pressures.
Of particular concern is the finding that dual
erm(B)+mef(A)–encoded resistance was most prevalent in
isolates collected from pediatric patients. By year 3 of the
study, 8.7% of all S. pneumoniae isolates collected from
children <14 years of age and 10.7% of those collected
from children <2 years of age exhibited this form of
Streptococcus pneumoniae with erm(B) and mef(A) Resistance
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Figure. Phylogenetic relationships of the 82 different sequence
type variations found in 518 Streptococcus pneumoniae isolates
with combined erm(B)- and mef(A)-mediated macrolide resistance
collected during the PROTEKT global study (1999–2003, n = 366)
and the PROTEKT US study (2000–2003, n = 152) compared with
the 20 PMEN (Pneumococcal Molecular Epidemiology Network
[29]) clones.macrolide resistance. The introduction of the 7-valent
pneumococcal vaccine (PCV7) in 2000 was aimed prima-
rily at reducing the incidence of disease in this vulnerable
group. While recent evidence suggests that this reduction
has occurred (37,38), the vaccine does not provide cover-
age against all S. pneumoniae serotypes. As discussed
above, most dual erm(B)+mef(A) isolates characterized in
this study are of serotype 19A (the prevalence of which
increased from years 1 to 3) or 19F. Although serotype 19F
is represented in the PCV7 vaccine, it affords low levels of
protection against upper respiratory infections such as oti-
tis media (39) and has been shown recently to be the least
immunogenic of the vaccine serotypes (40). Moreover, lit-
tle evidence shows that 19F provides cross-protection
against serotype 19A. The trends reported in this article
indicate that the introduction of routine immunization has
not prevented the spread of this nonvaccine serotype mul-
tidrug-resistant clone in the pediatric population and may
have contributed to the selection of serotype 19A strains.
In summary, although pneumococcal macrolide resist-
ance rates appear to have stabilized in the United States,
prevalence of clonal isolates with the combined
erm(B)+mef(A) genotype is increasing. These strains show
high-level macrolide and multidrug resistance, and their
spread across the United States represents a serious public
health concern. These findings also highlight the critical
need for continued monitoring of pneumococcal resistance
patterns over time, in particular, the spread of these mul-
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local or regional resistance patterns when selecting empir-
ic antibacterial treatment for community-acquired respira-
tory tract infections.
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